Free Trial

Fate Therapeutics Q1 2023 Earnings Report

Fate Therapeutics logo
$0.73 +0.05 (+7.65%)
As of 11:49 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Fate Therapeutics EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.55
Beat/Miss
Beat by +$0.36
One Year Ago EPS
-$0.68

Fate Therapeutics Revenue Results

Actual Revenue
$58.98 million
Expected Revenue
$33.53 million
Beat/Miss
Beat by +$25.45 million
YoY Revenue Growth
+220.50%

Fate Therapeutics Announcement Details

Quarter
Q1 2023
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Remove Ads

Fate Therapeutics Earnings Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Fate Therapeutics price target lowered to $2.50 from $3 at BofA
See More Fate Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fate Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fate Therapeutics and other key companies, straight to your email.

About Fate Therapeutics

Fate Therapeutics (NASDAQ:FATE), a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

View Fate Therapeutics Profile

More Earnings Resources from MarketBeat